Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir and Asunaprevir in IFN-Intolerant/Ineligible HCV GT1b
NCT01995266Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of daclatasvir, asunaprevir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Started Feb 2014; status: completed.
02
Drugs
daclatasvirasunaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01995266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01995266.